Although the actual sensitivity of stem and non-stem tumor cells to MDM2 inhibitors in patients’ tumors also remains to be investigated, possible differential sensitivity needs to be considered when interpreting the findings of ongoing trials or designing new trials. Here, MDM2 is linked to neoplasm.